Safety and Tolerability of ASA404 Administered in Combination With Docetaxel in Japanese Patients With Solid Tumors

NCT01285453 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

9

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced or Recurrent Solid Tumors

Interventions

DRUG: vadimezan

Sponsor

Novartis Pharmaceuticals